Project
I4V-MC-JAIM
Completed - recruitment closed ยท 2020 until 2022
Peischl Riana, Rubbert-Roth Andrea, Bartz-Batliner Mira
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed - recruitment closed
Start Date
2020
End Date
2022
Financing
Others
Study Design
patients randomized to active treatment, baricitinib 4mg daily or baricitinib 2mg daily, during study JAHZ or JAIA will continue on the same, blinded, dose of baricitinib in study JAIM. patients randomized to placebo during JAHZ or JAIA will be randomized 1:1 to receive baricitinib 4mg or 2mg daily during study JAIM. the treatment period will last up to 156 weeks from enrollment into study JAIM.
Brief description/objective
a phase 3, double-blind, multicenter study of evaluate the long-term safety and efficacy of baricitinib in patients with SLE.